AstraZeneca unveils positive results for arthritis treatment study

Biopharmaceutical business AstraZeneca has unveiled positive results from a study of fostamatinib, an oral drug being developed for the treatment of rheumatoid arthritis.

Biopharmaceutical business AstraZeneca has unveiled positive results from a study of fostamatinib, an oral drug being developed for the treatment of rheumatoid arthritis.

In the FTSE 100 company's phase III study, designed to assess the efficacy and safety of fostamatinib, the drug achieved a "statistically significant improvement" in the ACR20 [American College of Rhematology] response rate in patients compared to a placebo.

The ACR score represents the percentage improvement in symptoms in patients, such as tenderness and swelling in the joints.

To qualify for an ACR20, a number of criteria need to be fulfilled. This includes a person with rheumatoid arthritis having at least 20% fewer tender joints and at least 20% fewer swollen joints.

In the study, entitled OSKIRA-1, AstraZeneca said that fostamatinib achieved a "statistically significant improvement in ACR20 response rate at 24 weeks in both the 100 mg twice daily group and the group that received 100 mg twice daily for four weeks followed by 150 mg once daily" when compared to placebo.

The group added that fostamatinib did not demonstrate a statistically significant difference in mTSS [modified Total Sharp Score] compared to placebo at 24 weeks for either dose.

The radiographic modified Total Sharp Score is measured in the hands and feet using X-rays. mTSS is a measure of bone erosion and joint space narrowing on X-rays. A smaller change in mTSS over a given time period, given in percentage change of mTSS score, reflects less progression of joint damage.

AstraZeneca further reported that the safety and tolerability findings for fostamatinib observed in the OSKIRA-1 study were generally consistent with those previously reported for the TASKi Phase II programme.

Briggs Morrison, Managing Director and Executive Vice President of Global Medicines Development and Chief Medical Officer at AstraZeneca, said: "These top-line results provide important information on the efficacy and safety of fostamatinib and demonstrate that the compound has an effect on the signs and symptoms of rheumatoid arthritis.

"We will await the results of the remaining Phase III studies, OSKIRA-2 and OSKIRA-3, to further evaluate and characterise the profile of fostamatinib as a potential treatment for rheumatoid arthritis."

The OSKIRA-2 and OSKIRA-3 results are expected later in the second quarter of 2013.

MF

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

Negative interest rates and the end of free bank accounts
Bank accounts

Negative interest rates and the end of free bank accounts

Negative interest rates are likely to mean the introduction of fees for current accounts and other banking products. But that might make the UK bankin…
19 Oct 2020
UK post-Covid recovery stocks: these 20 companies could be set to rocket
Share tips

UK post-Covid recovery stocks: these 20 companies could be set to rocket

Finding stocks with the potential to rise tenfold or even further is far easier said than done. But the pandemic has produced the most promising backd…
22 Oct 2020
Why commodities could be the best investment for 2021
Commodities

Why commodities could be the best investment for 2021

There’s plenty for investors to worry about right now. But things will inevitably recover. And the sector most likely to do best when they do, says Jo…
22 Oct 2020